同济大学学报（医学版）2024，Vol.45Issue(4)：465-470,6.DOI:10.12289/j.issn.2097-4345.24194
2024 CSCO非小细胞肺癌指南(晚期部分)解读
Interpretation on updates of advanced diseases in CSCO non-small cell lung cancer guideline 2024
摘要
Abstract
During the past year,significant findings in advanced non-small cell lung cancer(NSCLC)have been reported or updated from various clinical studies,and the treatment of advanced NSCLC has ushered in more therapeutic options with better efficacy and safety.Based on the evidence during March 2023 to February 2024,the Chinese Society of Clinical Oncology(CSCO)has updated the guideline to 2024 edition.The updates in this edition for the advanced NSCLC include sections of the treatment of EGFR-sensitive mutations,EGFR exon 20 insertions,ALK fusions,ROS 1 fusions,BRAF V600 mutations,MET 14 exon jumping mutations,RET fusions,and HER2 mutations,as well as sections of the immune monotherapy and antibody-drug conjugate(ADC)for advanced NSCLC with no driver genes.This article will provide a detailed interpretation of these updates in CSCO NSCLC Guidelines regarding 2024.关键词
晚期非小细胞肺癌/CSCO指南/靶向治疗/免疫治疗Key words
advanced non-small cell lung cancer/CSCO guidelines/targeted therapy/immunotherapy分类
医药卫生引用本文复制引用
王家乐,邱天羽,崔亚男,任胜祥..2024 CSCO非小细胞肺癌指南(晚期部分)解读[J].同济大学学报（医学版）,2024,45(4):465-470,6.基金项目
国家自然科学基金项目(82373319) （82373319）
上海市优秀学术带头人项目(21XD1423200) （21XD1423200）
